Journal of Clinical Oncology Q1 Unclaimed

American Society of Clinical Oncology United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.

Journal of Clinical Oncology focuses its scope in these topics and keywords: cancer, patients, phase, breast, study, clinical, trial, advanced, treatment, therapy, ...

Type: Journal

Type of Copyright: CC BY-NC-ND

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Price

3166 €

Gold OA

-

Green OA

- €

Non OA

Metrics

Journal of Clinical Oncology

10,054

SJR Impact factor

525

H Index

574

Total Docs (Last Year)

2341

Total Docs (3 years)

14282

Total Refs

26112

Total Cites (3 years)

1352

Citable Docs (3 years)

19,71

Cites/Doc (2 years)

24,88

Ref/Doc

Aims and Scope


cancer, patients, phase, breast, study, clinical, trial, advanced, treatment, therapy, ii, iii, metastatic, randomized, lung, chemotherapy, prostate, results, group, radiotherapy, treated, cancer, tumor, oncology research, medicine


Best articles

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

View more

A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease.

View more

ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

View more

ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.

View more

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

View more

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

View more

Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492

View more

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma

View more

Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry.

View more

Breast Cancer Screening in Women Previously Treated for Hodgkin's Disease: A Prospective Cohort Study

View more

Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission

View more

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

View more
SHOW MORE ARTICLES

Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

View more

Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study

View more

Classical Hodgkin's Disease and Follicular Lymphoma Originating From the Same Germinal Center B Cell

View more

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

View more

Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.

View more

Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications

View more

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators

View more

Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group.

View more

Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma

View more

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

View more

Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.

View more

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

View more

Comments

No comments ... Be the first to comment!